CD19 and neoplasm: Similarly, the CD19-CAR construct targeted to the eSHS6 site mentioned above showed sustainable CAR expression with or without antigen stimulation, effectively lysed CD19+ NALM6 cells, and provided long-term tumor control in an NSG (NOD/SCID/IL-2Rγ null) model of B-cell ALL [44].